Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin-α in Metabolic Dysfunction-Associated Steatotic Liver Disease
NCT07381257Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rifaximin in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Relative change in liver fat content measured by MRI at 24 weeks. Started Jan 2026; status: recruiting.
02
Drugs
rifaximin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT07381257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07381257.